$4.05
+0.00 (+0.00%)
USD · as of 2026-08-14 · marketstack
stale — last close 2026-08-14, not a live quote
Clinical trials
catalyst calendar across sponsors →Studies where LIXT is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional
Held by 0 tracked-famous managers · FINRA short interest 1.4 days to cover (settled 2026-06-30) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)NCT03886662For Phase Ib - Number of patients with adverse events related to the study treatment as a measure of safety and tolerability of LB-100 study drugOpen-label · Treatment | Phase 1/2 | Recruiting | Drug: LB-100 | Myelodysplastic Syndromes | 47 | May 2021 | 2019-04-08 |
| Phase I Study of LB-100 With Docetaxel in Solid TumorsNCT01837667Number of patients with adverse events as a measure of safety and tolerability of LB-100 for Injection treatment plus docetaxel.Open-label · Treatment | Phase 1 | Completed | Drug: LB-100 for Injection, Docetaxel | Tumors, Neoplasms, Cancer | 29 | Sep 2016actual | 2017-01-24 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19